Scheinberg Adam, Hall Kate, Lam Lawrence T, O'Flaherty Stephen
Department of Rehabilitation, Centre for Trauma Care, Prevention, Education, and Research, The Royal Alexandra Hospital for Children, Sydney, Australia.
J Paediatr Child Health. 2006 Nov;42(11):715-20. doi: 10.1111/j.1440-1754.2006.00957.x.
To assess the effectiveness of oral baclofen in reducing spasticity and improving function in children with cerebral palsy.
A double-blind, randomised cross-over pilot study of oral baclofen versus placebo. Assessment tools included the Goal Attainment Scale, Pediatric Evaluation of Disability Inventory, Modified Tardieu Scale and parent questionnaire.
Fifteen children with mean age 7.4 years (SD=2.7 years) and spastic or spastic/dystonic quadriplegia (Gross Motor Function Classification System Level IV or V) were enrolled. Children scored significantly better on the Goal Attainment Scale with baclofen compared with placebo (F(1,13)=4.5, P=0.05). There was no significant difference between baclofen and placebo for the Pediatric Evaluation of Disability Inventory or Modified Tardieu Scale. Parent questionnaire results are described.
This pilot study demonstrates that oral baclofen has an effect beyond placebo in improving goal-oriented tasks, such as transfers, in children with spastic quadriplegic cerebral palsy.
评估口服巴氯芬对降低脑瘫患儿痉挛程度及改善功能的有效性。
一项口服巴氯芬与安慰剂对比的双盲、随机交叉试验性研究。评估工具包括目标达成量表、儿童残疾评定量表、改良塔迪厄量表及家长问卷。
纳入15名平均年龄7.4岁（标准差=2.7岁）、患有痉挛型或痉挛/张力障碍型四肢瘫（粗大运动功能分类系统IV级或V级）的儿童。与安慰剂相比，服用巴氯芬的儿童在目标达成量表上得分显著更高（F(1,13)=4.5，P=0.05）。在儿童残疾评定量表或改良塔迪厄量表方面，巴氯芬与安慰剂之间无显著差异。描述了家长问卷结果。
这项试验性研究表明，口服巴氯芬在改善痉挛型四肢瘫脑瘫患儿的目标导向性任务（如转移）方面，效果优于安慰剂。
